AllDocs -> cancers

Fas and Fas-ligand expression in human pancreatic cancer . Kornmann M, Ishiwata T, Kleeff J, Beger HG, Korc M. Department of Medicine, University of California, Irvine 92697, USA. OBJECTIVE: To investigate Fas and FasL expression in pancreatic tissues and cultured pancreatic cancer cell lines, and to assess the ability of anti-Fas antibodies to induce apoptosis. SUMMARY BACKGROUND DATA: Activation of the Fas receptor by Fas-ligand (FasL) results in apoptosis, and dysregulation of this pathway may contribute to abnormal cell proliferation. METHODS: Northern blotting and immunohistochemistry were used to compare Fas and FasL expression in normal and cancerous tissues. DNA 3'-OH end labeling was used to detect apoptotic cells. The effects of Fas activation on cell growth and signaling pathways were investigated in culture. RESULTS: Pancreatic cancers exhibited increased Fas RNA levels, whereas ...

Abstract. Pancreatic cancer is a malignant tumor with an extremely poor prognosis. The mechanisms of the aggressive growth and metastasis are not yet extensively understood. Over-expression of epidermal growth factor receptor (EGFR) was suggested to be associated with malignant transformation of pancreatic cancer . We examined EGFR expression in 77 cases of invasive ductal adenocarcinoma of the pancreas, and analyzed the relation between the EGFR expression pattern and clinicopathological factors. EGFR immunoreactivity was detected in 41.6% (32/77) of human pancreatic cancers; i.e. diffuse expression in 32.5% (25/77) and focal expression in 9.1% (7/77). The EGFR expression was associated with gender (p<0.05), histological differentiation (p<0.05) and metastatic status of TNM classification (p<0.01). The observations suggested that EGFR expression plays important roles in ...

Abstract. The proteinase-activated receptor-2 (PAR-2) is a G protein-coupled receptor that is cleaved and activated by trypsin. To clarify the presence of PAR-2 in human pancreatic cancer , the expression of PAR-2 was analyzed by RT-PCR, immunoblotting and immunocytochemistry using 5 human pancreatic cancer cell lines. And to evaluate the biological significance, immunohistochemical expression of PAR-2 in malignant and non-malignant human pancreatic tissues was examined using paraffin-embedded sections. The presence of PAR-2 was confirmed in all 5 pancreatic cancer cell lines and all 21 paraffin-embedded specimens from human pancreatic cancer examined. The expression of PAR-2 was found to be higher in the tissues with infiltrative growth pattern than those with expansive growth pattern. Moreover, significantly higher expression of PAR-2 was observed in the tissues ...

H:\EVERYONE\SYSTEMIC\Chemo\Protocol\GI\GIPGEM_aug2003.doc GIPGEM LAST REVISED: 1 Dec 2000 Page 1 of 3 BCCA Protocol Summary for Palliative Chemotherapy for Pancreatic Adenocarcinoma Cancer Using Gemcitabine Protocol Code: GIPGEM Tumour Group: Gastrointestinal Contact Physician: GI Systemic Therapy ELIGIBILITY: • Metastatic or unresectable pancreatic adenocarcinoma • ECOG 0-2 • Class II form must be completed for first 6 cycles. For further cycles, an “Individual use of Benefit Drug List Medication for an Undesignated Indication” form must be completed and approved. TESTS: Baseline: CBC, diff and platelets; creatinine, bilirubin, appropriate tumour markers and imaging study Before each treatment: CBC, diff and platelets If clinically indicated: bilirubin, creatinine After cycle 1, then every 2 cycles: appropriate ...

H:\Pharm-prov\UPDATE\UpdateImplementation\GI protocols_contact revised\GIPGEM_nov2003.docGIPGEM LAST REVISED: 1 Dec 2000 Page 1 of 3 BCCA Protocol Summary for Palliative Chemotherapy for Pancreatic Adenocarcinoma Cancer Using Gemcitabine Protocol Code: GIPGEM Tumour Group: Gastrointestinal Contact Physician: GI Systemic Therapy ELIGIBILITY: • Metastatic or unresectable pancreatic adenocarcinoma • ECOG 0-2 • Class II form must be completed for first 6 cycles. For further cycles, an “Individual use of Benefit Drug List Medication for an Undesignated Indication” form must be completed and approved. TESTS: Baseline: CBC, diff and platelets; creatinine, bilirubin, appropriate tumour markers and imaging study Before each treatment: CBC, diff and platelets If clinically indicated: bilirubin, creatinine After cycle 1, then every ...

Pancreatic cancer remains a cancer with poor survival prospects. For males there has been no change in incidence or mortality over the last 20 years, and for females there has been only a slight increase in both measures. Background notes Pancreatic Cancer Page 2 Male Pancreatic Cancer - Incidence and Mortality* 1977-2000 All Ages Source - SA Cancer Registry Data 0 2 4 6 8 10 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 Year *Age Standardised for World Population Ra te/ 10 00 00 Incidence Mortality Male Pancreatic Cancer ~ Incidence and Mortality* 1977-2000 All Ages Source: SA Cancer Registry Data ...

KIMBA ROXBY DOWNS (M) COOBER PEDY (DC) UNINCORP. FAR NORTH UNINCORP. FLINDERS RANGES ROBE BERRI CLARE HAWKER CEDUNA TANUNDA WHYALLA MENINGIE WILLUNGA MAITLAND PORT PIRIE BORDERTOWN PORT LINCOLN PETERBOROUGH PORT AUGUSTA MOUNT GAMBIER PORT BROUGHTON 0 100 200 50 Kms Incidence of Pancreatic Cancer in South Australia, 1991-2000 by Statistical Local Areas GAWLER GLENELG MODBURY WILLUNGA ADELAIDE WOODVILLE ELIZABETH MOUNT BARKER BEDFORD PARK NOARLUNGA CENTRE Annual Incidence/100,000 0.0 - 2.5 2.6 - 5.0 5.1 - 10.0 10.1 - 75.0 Towns Statistical Local Areas Produced by: Data Analysis and Consulting Unit, Information Management Services, and Epidemiology Branch, Department of Human Services. Data Sources: ...

KIMBA ROXBY DOWNS (M) COOBER PEDY (DC) UNINCORP. FAR NORTH UNINCORP. FLINDERS RANGES ROBE BERRI CLARE HAWKER CEDUNA TANUNDA WHYALLA MENINGIE WILLUNGA MAITLAND PORT PIRIE BORDERTOWN PORT LINCOLN PETERBOROUGH PORT AUGUSTA MOUNT GAMBIER PORT BROUGHTON 0 100 200 50 Kms Pancreatic Cancer Mortality in South Australia, 1991-2000 by Statistical Local Areas GAWLER GLENELG MODBURY WILLUNGA ADELAIDE WOODVILLE ELIZABETH MOUNT BARKER BEDFORD PARK NOARLUNGA CENTRE Annual Mortality/100,000 0.0 - 2.5 2.6 - 5.0 5.1 - 10.0 10.1 - 65.0 Towns Statistical Local Areas Produced by: Data Analysis and Consulting Unit, Information Management Services, and Epidemiology Branch, Department of Human Services. Data Sources: ...

JOP. J Pancreas (Online) 2004; 5(4):29001-29015. JOP. Journal of the Pancreas – http://www.joplink.net – Vol. 5, No. 4 – July 2004. [ISSN 1590-8577] 29001 ROUND TABLE Defining the Diagnostic Algorithm in Pancreatic Cancer John David Horwhat, Frank G Gress Division of Gastroenterology, Department of Medicine, Duke University Medical Center. Durham, North Carolina, USA Summary Most patients with pancreatic cancer present with a mass on radiologic studies, however, not every pancreatic mass is cancer . Since radiological studies alone are insufficient to establish the diagnosis of a pancreatic mass and patient management depends on a definitive diagnosis; confirmatory cytology or histology is usually required. As a minimally invasive procedure, EUS and EUS FNA avoid the risk of cutaneous or peritoneal contamination that may occur with ...

JOP. J Pancreas (Online) 2004; 5(4):27001-27005. JOP. Journal of the Pancreas – http://www.joplink.net – Vol. 5, No. 4 – July 2004. [ISSN 1590-8577] 27001 ROUND TABLE Note: Look at the red text Pancreatic Cancer Imaging: Which Method? Erwin Santo Department of Gastroenterology and Liver Diseases, Tel Aviv Sourasky Medical Center. Tel Aviv, Israel Summary Pancreatic cancer is the 10 th most common malignancy and the 4 th largest cancer killer in adults. Surgery offers the only chance of curing these patients. Complete surgical resection is associated with a 5-year survival rate of between 20 and 30%. The challenge is how to best select those patients for curative surgery. Early studies demonstrated excellent sensitivity of EUS in detecting pancreatic tumors in comparison to CT. Similarly, ...

Last revised: 4/14/04 UM Cancer Center Patient Education Document #0033 Apr04 Ed. Online version: http://www. cancer .med.umich.edu/learn/percpathways.htm University of Michigan Comprehensive Cancer Center Patient Education Resource Center (PERC) INFORMATION GUIDE Pancreatic Cancer The purpose of this information guide is to help patients newly diagnosed with Pancreatic Cancer and their families to find sources of information and support. This list is not meant to be comprehensive, but rather to provide starting points for information seeking. The materials can be found at the Patient Education Resource Center at the University of Michigan Comprehensive Cancer Center in room B1-361. Brochure Available free at the Patient Education Resource Center on Level B-1 room 361 National Cancer ...

JOP. J Pancreas (Online) 2004; 5(4):240-242. JOP. Journal of the Pancreas – http://www.joplink.net – Vol. 5, No. 4 – July 2004 240 PANCREAS NEWS Screening Tests for Pancreatic Cancer : Searching for the Early Symptoms or the Population at Risk Raffaele Pezzilli Department of Internal Medicine, Sant'Orsola-Malpighi Hospital. Bologna, Italy In the past four decades, the incidence of pancreatic cancer has increased steadily in most of the world and now this type of tumor ranks as the fifth or sixth most frequent cause of death due to cancer in many western countries [1]. For example, in 2000, worldwide figures for pancreatic cancer were projected at 216,400 new cases and 213,500 deaths [2]; the data coming from the United States in 2004, estimated that 31,860 patients would be diagnosed with pancreatic cancer and 31,270 would ...

Golf Outing and Barbecue Grandview Golf Course • 2779 Carlisle Road • York, PA 17404 Saturday, October 16, 2004 DEADLINE FOR SUBMISSION IS SEPTEMBER 18 Name Company Address City State Zip Phone E-mail Send ad and check made payable to PanCAN to: 5812 Barnsley Dr • Harrisburg, PA 17111 Questions Please call (717) 540-9110 or e-mail teamhopecpa@comcast.net PROGRAM ADVERTISEMENT OPPORTUNITIES Inside front or back cover (5” x 7 1/2”) . $200.00 each Full Page (5” x 7 1/2”) $100.00 each Half Page (5” x 3 1/2”) . $75.00 each In Honor/In Memory Of .. $50.00 each In Loving Memory Robert R. Moore 1961-1999 In memory of Linda G. Hammen September 5, 1942 - July 7, 2001 A wonderful Wife, loving Mother and Gram-mom with a ...

Pancreatic Cancer 2004 Advances and Challenges June 25-26, 2004 Grand Hyatt, San Francisco, CA Annual Symposium of The Lustgarten Foundation for Pancreatic Cancer Research in collaboration with the American Association for Cancer Research and the University of California, San Francisco Conference Chairperson: Margaret A. Tempero, M.D., University of California, San Francisco, CA Abstract and Advance Registration Deadline: May 14, 2004 www.aacr.org Page 2 Annual Symposium of the Lustgarten Foundation for Pancreatic Cancer Research in collaboration with the American Association for Cancer Research and the University of California, San Francisco Conference Chairperson Margaret A. Tempero, M.D. Deputy Director, UCSF Comprehensive ...

with medical, surgical and radiation oncologists. "The University of Chicago has expertise in every single field that deals with pancreatic cancer ," says Irving Waxman, MD, director of endoscopy at the University of Chicago and a founder of the pancreatic cancer center. From interventional endoscopy to genetics to pathology, from radiation therapy to surgery, and from standard chemotherapies to phase I, II and III trials of investigational drugs, "we have nationally known physician-scientists at every stage," Waxman said. "This is a very comprehensive program," confirms co-director Fabrizio Michelassi, MD, vice chairman of the department of surgery and section chief of general surgery. "We have strengths in all aspects of diagnosis and treatment of pancreatic cancer ." This depth, combined with the multi- disciplinary approach, is quite ...

Tumori, 90: 192-195, 2004 Correspondence to: Ozkan Kanat, MD, Uludag University Faculty of Medicine Department of Medical Oncology, Gorukle 16059, Bursa, Turkey. Tel +90-224-4428400; fax +90-224-4428049; e-mail ozkanat@uludag.edu.tr Received July 7, 2003; accepted September 8, 2003. TREATMENT OF METASTATIC PANCREATIC CANCER WITH A COMBINATION OF GEMCITABINE AND 5-FLUOROURACIL: A SINGLE CENTER PHASE II STUDY Ozkan Kanat, Turkkan Evrensel, Ender Kurt, Mutlu Demiray, Guzin Gonullu, Murat Arslan, and Osman Manavoglu Department of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, Turkey Key words: chemotherapy, gemcitabine, 5-fluorouracil, pancreatic cancer . Aim : To determine the activity and toxicity of a combination of weekly gemcitabine and 5-fluorouracil bolus intravenously in patients with metastatic pancreatic cancer . Patients ...

Tumori, 90: 192-195, 2004 Introduction Metastatic pancreatic cancer (MPC) is a very aggres- sive and highly lethal disease. The median survival of patients with MPC is approximately 3 to 6 months. It is one of the neoplasm most resistant to chemotherapy. For this reason, the medical management of the disease presents a considerable therapeutic challenge to the on- cologist. Many chemotherapy drugs have been tested in the treatment of MPC, and the results have been disap- pointing. However, clinical trials have demonstrated that chemotherapy may alleviate some disease-related debilitating symptoms, such as pain, weight loss and fa- tigue, and may improve the patient’s quality of life. 5-Fluorouracil (5-FU) is the most extensively studied and most widely used agent in the treatment of MPC. It is the standard care for patients with MPC. However, the re- sults obtained with this ...

A Novel Gene Transfer Therapy Against Pancreatic Cancer (TNFerade) Delivered by Endoscopic Ultrasound (EUS) and Percutaneous Guided Fine Needle Injection (FNI) Kenneth Chang, Nader Hanna, Stephen Swisher, Theodore Chung, J. Randolph Hecht, Stephen Vogel, Alexander Rosemurgy, John Nemunaitis, John Gibbs, Tony Reid, Jennifer Macko, Paul Kessler, Mitchell Posner, James Farrell, Shane Grundy, Harlan Pinto, Roy Soetikno, Irving Waxman, Neil Senzer A Novel Gene Transfer Therapy Against A Novel Gene Transfer Therapy Against Pancreatic Cancer ( Pancreatic Cancer ( TNFerade TNFerade ) Delivered by ) Delivered by Endoscopic Endoscopic Ultrasound (EUS) and Ultrasound (EUS) and Percutaneous Percutaneous Guided Fine Needle Injection (FNI) Guided Fine Needle Injection (FNI) Kenneth Chang, ...

Fifteenth Annual Fanconi Anemia Research Fund Scientific Symposium Fanconi Anemia Gene Defects in Pancreatic Cancer M. S. van der Heijden 1 , J. R. Brody 1 , E. Gallmeier 1 , R. H. Hruban 1,2 and S. E. Kern 1,2 1 Department of Oncology, 2 Departments of Pathology and Oncology, Johns Hopkins University, Baltimore, Maryland Pancreatic cancer is the fifth leading cause of death from cancer in the United States. It harbors the highest percentage of BRCA2 mutations of all human cancers: 7-10% in sporadic cancer and up to 17% in cases with a strong familial pattern. Mutations in BRCA2 have been shown by Howlett et al. to be responsible for a subgroup of Fanconi anemia. We recently identified inherited and somatic variations of FANCC and FANCG in young-onset pancreatic ...

PANCREATIC CANCER - All Sections PANCREATIC CANCER What Is Cancer ? Cancer develops when cells in a part of the body begin to grow out of control. Although there are many kinds of cancer , they all start because of out-of-control growth of abnormal cells. Normal body cells grow, divide, and die in an orderly fashion. During the early years of a person's life, normal cells divide more rapidly until the person becomes an adult. After that, cells in most parts of the body divide only to replace worn-out or dying cells and to repair injuries. Because cancer cells continue to grow and divide, they are different from normal cells. Instead of dying, they outlive normal cells and continue to form new abnormal cells. Cancer cells can travel to other parts of the body where they begin to grow and replace normal tissue. This process, called metastasis , occurs as the cancer ...

Recent advances on Hepato-billary- pancreatic Cancer Aichi Cancer Center International Symposium III International Conference Hall Aichi Cancer Center Nagoya, Japan December 13-14, 1996 Page 2 1 Aichi Cancer Center International Symposium III Recent advances on Hepato-biliary- pancreatic Cancer Committee of the Aichi Cancer Center International Symposium Chairperson: Makoto Ogawa Shigeru Kawamoto Noboru Shimomura Morikuni Murakami Tsuyoshi Kito Takashi Hirai Suketami Tominaga Toshitada Takahashi Masao Seto Organizing committee of the Third Symposium Chairperson : Kazuhiko Ohhashi Yasuaki Arai Takeshi Morimoto Kenzo Yasui Junichi Sakamoto Masae Tatematsu Osamu Takagi Page 3 2 Friday, December ...

pancreatic cancer TESTIMONIAL: PANCREATIC CANCER STAGE IV Patient: Carmen Quezada Date of Treatment: June 2002 Date of Testimonial: Sept 30, 2002 Diagnosis Date: May 2002 In May of 2002, I was diagnosed with pancreatic cancer . I had bypass surgery and my doctors gave me eight months to live. They said that I would most likely be bedridden. My family sought alternative treatment methods in the hope of giving me a longer lifetime as well as a decent quality of life. Six days after leaving the hospital I began Lymphocyte Activated Killer Cell Treatment and Dendritic Cell Therapy. It is now the end of September-- I can honestly say that I feel relatively okay. I am thankful that I am not bedridden. I am able to walk and take care of myself. ...

pancreatic cancer Novel Approach to Combat Pancreatic Ductal Adenocarcinoma by Attacking MUC4 Bob Kelly MOL523 29 April 2004 Epidemiology of Pancreatic Cancer 30,000 Americans diagnosed annually fifth highest cancer mortality rate in US low 5-year survival rate (1-3%) insensitivity to current treatments poor detection rapid metastasis risk factors www. cancer .gov What target to attack? p16INK4a p53 SMAD4/DPC4 BRCA2 KRAS2 HER-2/neu (ErbB2) MUC4 LKB1/STK11 Hanahan, D., and Weinberg, R.A. Figur e 1 Properties of Mucins glycoproteins can be membrane-associated or soluble form protective layer to combat proteases, acidic environment, exposure to microorganisms ...

RISK FACTOR INFORMATION FOR SELECTED CANCER TYPES Source: Community Assessment Unit, Bureau of Environmental Health Assessment, Massachusetts Department of Public Health December, 2002 Pancreatic Cancer The American Cancer Society estimates that approximately 30,300 people in the U.S. (14,700 men and 15,600 women) will develop pancreatic cancer in 2002. This disease accounts for approximately 2% of all new cases of cancer in both men and women, but between 5% and 6% of all cancer deaths (ACS, 2002). This discrepancy has been attributed to detection of pancreatic cancer at an advanced stage and the short median survival time for this cancer of approximately three months. Between 1920 and 1965, mortality from this disease increased nearly 200% from 2.9 to 8.2 per 100,000 people. These increases are believed to be due, in part, to improved diagnosis during ...